Evaluation of the possibility of using fecal calprotectin for the diagnosis of inflammatory bowel diseases in patients with ankylosing spondylitis
- 24 June 2026
- journal article
- Published by Alfmed LLC in Medical alphabet
- No. 12
Abstract
The aim . To evaluate the possibility of using fecal calprotectin levels for early diagnosis of inflammatory bowel diseases in patients with AS in real clinical practice. Materials and methods . The analysis included 70 patients with a confirmed diagnosis of AS over the age of 18: 52 men (74.3 %) and 18 women (25.7 %), aged 47.4±8.8 years, with a disease duration of 19.6±7.9 years. All patients underwent blood tests (ESR, CRP, HLAB 27 antigen levels), esophagogastroduodenoscopy and colonoscopy, quantitative analysis of the fecal calprotectin levels using the method of lateral immunochromatography with the BUHLMANN Quantum Blue rapid test (standart range: 100–1800 μg/g). Results . All patients had high disease activity: BASDAI was 5.4±1.4, ASDAS CRP – 3.6±0.8. IBD was diagnosed in 18 cases (25.7 %). In 77 % of patients with AS, the FC level exceeded 100 μg/g, and in 28 % it exceeded 1800 μg/l. The FC level was more than 1000 μg/g in 63 %. In patients with IBD, the FC level was more than 100 μg/g, and the average FC level was higher in patients with IBD (1141.3 μg/g) than without IBD (787 μg/g). No active IBD was detected in all patients with FC levels less than 300 μg/g of feces. FC levels correlated with CRP (r=0.366) and ESR (r=0.366) (pConclusion . Patients with AS and IBD had higher FC levels than patients without IBD. Normal FC levels in patients with AS indicate the absence of intestinal inflammation. There was also a correlation between increased FC levels and the severity of AS. According to the study, measuring fecal calprotectin levels may be useful for detecting intestinal inflammation at an early stage.Keywords
This publication has 40 references indexed in Scilit:
- Serum biomarkers and their relationship to axial spondyloarthritis associated with inflammatory bowel diseasesAutoimmunity Reviews, 2023
- NSAIDs, gastrointestinal toxicity and inflammatory bowel diseaseGastroenterología y Hepatología (English Edition), 2022
- Investigation of asymptomatic intestinal inflammation in ankylosing spondylitis by fecal calprotectinArab Journal of Gastroenterology, 2021
- Calprotectin in spondyloarthritis: A systematic review and meta-analysisInternational Immunopharmacology, 2020
- Fecal Calprotectin, Gut Inflammation and SpondyloarthritisArchives of Medical Research, 2019
- Fecal Calprotectin2018
- European consensus on the histopathology of inflammatory bowel diseaseJournal of Crohn's and Colitis, 2013
- Fecal calprotectin is a surrogate marker for endoscopic lesions in inflammatory bowel diseaseInflammatory Bowel Diseases, 2012
- Ankylosing spondylitis and bowel diseaseBest Practice & Research Clinical Rheumatology, 2006
- Evaluation of Diagnostic Criteria for Ankylosing SpondylitisArthritis & Rheumatism, 1984